ATHA vs. PLX, JATT, CVM, CGTX, ALVR, DTIL, TIL, ATRA, CRIS, and ELUT
Should you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Protalix BioTherapeutics (PLX), JATT Acquisition (JATT), CEL-SCI (CVM), Cognition Therapeutics (CGTX), AlloVir (ALVR), Precision BioSciences (DTIL), Instil Bio (TIL), Atara Biotherapeutics (ATRA), Curis (CRIS), and Elutia (ELUT). These companies are all part of the "biological products, except diagnostic" industry.
Protalix BioTherapeutics (NYSE:PLX) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations.
Protalix BioTherapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 773.36%. Athira Pharma has a consensus price target of $19.00, suggesting a potential upside of 653.97%. Given Athira Pharma's higher probable upside, equities research analysts plainly believe Protalix BioTherapeutics is more favorable than Athira Pharma.
Protalix BioTherapeutics has a net margin of 11.48% compared to Protalix BioTherapeutics' net margin of 0.00%. Athira Pharma's return on equity of 19.48% beat Protalix BioTherapeutics' return on equity.
Athira Pharma received 13 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 62.50% of users gave Protalix BioTherapeutics an outperform vote while only 58.06% of users gave Athira Pharma an outperform vote.
Protalix BioTherapeutics has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 5.0% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 19.8% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Protalix BioTherapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.83, suggesting that its stock price is 183% more volatile than the S&P 500.
In the previous week, Athira Pharma had 3 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 10 mentions for Athira Pharma and 7 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 0.86 beat Athira Pharma's score of 0.22 indicating that Athira Pharma is being referred to more favorably in the news media.
Summary
Protalix BioTherapeutics beats Athira Pharma on 9 of the 15 factors compared between the two stocks.
Get Athira Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Athira Pharma Competitors List
Related Companies and Tools
